Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT01940809	Phase II	Dabrafenib + Ipilimumab Ipilimumab + Nivolumab + Trametinib Dabrafenib + Ipilimumab + Trametinib Ipilimumab + Trametinib Dabrafenib + Ipilimumab + Nivolumab Ipilimumab Ipilimumab + Nivolumab Dabrafenib + Ipilimumab + Nivolumab + Trametinib	Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery	Terminated	USA	0
NCT01682083	Phase III	Dabrafenib + Trametinib	Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). (COMBI-AD)	Completed	USA \| SWE \| POL \| NZL \| NOR \| NLD \| ITA \| ISR \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	3
NCT02027961	Phase Ib/II	Dabrafenib + Durvalumab + Trametinib Durvalumab + Trametinib	Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone	Completed	USA \| ITA \| FRA \| CAN	0
NCT02200562	Phase Ib/II	Dabrafenib + Ipilimumab	Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma	Terminated	USA	0
NCT04655157	Phase Ib/II	Encorafenib + Ipilimumab + Nivolumab Binimetinib + Encorafenib + Ipilimumab + Nivolumab	Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma (QUAD01)	Terminated	USA	0
NCT01585415	Phase I	Vandetanib	Vemurafenib and White Blood Cell Therapy for Advanced Melanoma	Terminated	USA	0
NCT03551626	Phase III	Dabrafenib + Trametinib	Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus)	Completed	TUR \| SWE \| SVN \| SVK \| POL \| NOR \| LVA \| LTU \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| FIN \| CZE \| CAN \| BRA \| AUS \| ARG	3
NCT01989585	Phase Ib/II	Dabrafenib + Navitoclax + Trametinib Dabrafenib + Trametinib	Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	Active, not recruiting	USA	0
NCT04527549	Phase II	Dabrafenib + Trametinib Dabrafenib + Hydroxychloroquine + Trametinib	Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma	Terminated	USA	0
NCT02196181	Phase II	Dabrafenib + Trametinib	Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery	Active, not recruiting	USA	0
NCT02097225	Phase I	Dabrafenib + Onalespib + Trametinib	Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Terminated	USA	0
NCT03101254	Phase Ib/II	Cobimetinib + LY3022855 + Vemurafenib	LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma	Completed	USA	0
NCT02224781	Phase III	Ipilimumab + Nivolumab Dabrafenib + Trametinib	Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	Active, not recruiting	USA	0
NCT01909453	Phase III	Vemurafenib Encorafenib Binimetinib + Encorafenib	Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)	Completed	USA \| TUR \| SWE \| SVK \| POL \| NOR \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| AUS \| ARG	8
NCT01978236	Phase II	Dabrafenib + Trametinib Dabrafenib	Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites	Terminated	USA \| AUS	0
NCT01767454	Phase I	Dabrafenib + Ipilimumab + Trametinib Dabrafenib + Ipilimumab	Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma	Completed	USA	0
NCT03455764	Phase Ib/II	Dabrafenib + MCS110 + Trametinib	MCS110 With BRAF/MEK Inhibition in Patients With Melanoma	Completed	USA	0
NCT01495988	Phase II	Bevacizumab Vemurafenib	Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma	Terminated	USA	0
NCT01512251	Phase Ib/II	Buparlisib + Vemurafenib	BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma	Completed	USA	0
NCT01657591	Phase I	Vemurafenib + XL888	Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma	Completed	USA	0
NCT02427893	Phase III	Cobimetinib Vemurafenib	Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma	Withdrawn	USA	0
NCT01682213	Phase II	Dabrafenib	Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation	Completed	USA	0
NCT01781026	Phase II	Vemurafenib	Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases	Completed	USA	0
NCT06079333	Phase II	Dabrafenib + Trametinib	NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) (NEO-ATACT)	Recruiting	NLD	0
NCT01947023	Phase I	Dabrafenib + Lapatinib	Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery	Active, not recruiting	USA	0
NCT03272464	Phase I	Dabrafenib + Itacitinib + Trametinib	INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.	Terminated	USA	0
NCT03026517	Phase I	Dabrafenib + Phenformin + Trametinib	Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma	Completed	USA	0
NCT02818023	Phase I	Cobimetinib + Pembrolizumab + Vemurafenib	Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma	Terminated	USA	0

Profile Name	BRAF V600E/K
Gene Variant Detail	BRAF V600E/K (gain of function)
Relevant Treatment Approaches	BRAF Inhibitor MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor RAF Inhibitor (Pan)

Molecular Profile Detail

Contact

Filtering

Sorting